First Wave BioPharma to Participate in Maxim’s 2022 Virtual Growth Conference
March 22 2022 - 7:00AM
First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma”
or the “Company”), a clinical-stage biopharmaceutical company
specializing in the development of targeted, non-systemic therapies
for gastrointestinal (GI) diseases, announced today that James
Sapirstein, Chairman and Chief Executive Officer, will deliver a
virtual presentation at Maxim’s 2022 Virtual Growth Conference
being held March 28 – 30, 2022.
In a prerecorded presentation, available on-demand to all
registered conference attendees, Mr. Sapirstein will provide
an overview of First Wave BioPharma’s business and clinical
development programs, and highlight recent corporate achievements,
as well as anticipated milestones. Members of the company’s
management team will be available for one-on-one virtual
meetings.
Details of the conference are as follows:
Event: |
Maxim’s 2022 Virtual Growth Conference |
Date: |
March 28-30, 2022 |
Registration: |
https://m-vest.com/events/2022-virtual-growth-conference |
About First Wave BioPharma, Inc.
First Wave BioPharma is a clinical-stage
biopharmaceutical company specializing in the development of
targeted, non-systemic therapies for gastrointestinal (GI)
diseases. The Company is currently advancing a therapeutic
development pipeline with multiple clinical stage programs built
around its two proprietary technologies – niclosamide, an oral
small molecule with anti-viral and anti-inflammatory properties,
and the biologic adrulipase, a recombinant lipase enzyme designed
to enable the digestion of fats and other nutrients. First Wave
BioPharma’s niclosamide portfolio is led by two clinical programs
in Phase 2 clinical trials: FW-COV for COVID-19 gastrointestinal
infections and FW-UP for ulcerative proctitis (UP) and ulcerative
proctosigmoiditis. Three additional indications of niclosamide,
include FW-ICI-AC, for Grade 1 and Grade 2 Immune Checkpoint
Inhibitor-associated colitis and diarrhea in advanced oncology
patients, FW-UC (ulcerative colitis) and FW-CD (Crohn’s disease).
The Company is also advancing FW-EPI (adrulipase) for the treatment
of exocrine pancreatic insufficiency (EPI) in patients with cystic
fibrosis and chronic pancreatitis. First Wave BioPharma is
headquartered in Boca Raton, Florida. For more information visit
www.firstwavebio.com.
Forward-Looking Statement
This press release may contain certain
statements relating to future results which are forward-looking
statements. It is possible that the Company’s actual results and
financial condition may differ, possibly materially, from the
anticipated results and financial condition indicated in these
forward-looking statements, depending on factors including whether
results obtained in preclinical and nonclinical studies and
clinical trials will be indicative of results obtained in future
clinical trials; whether preliminary or interim results from a
clinical trial will be indicative of the final results of the
trial; the size of the potential markets for the Company’s drug
candidates and its ability to service those markets; the effects of
the First Wave Bio, Inc. acquisition and its announcement on the
Company’s business, operating results and financial prospects; the
integration of the First Wave Bio, Inc. business with the Company’s
own business; and the Company’s current and future capital
requirements and its ability to raise additional funds to satisfy
its capital needs. Additional information concerning the Company
and its business, including a discussion of factors that could
materially affect the Company’s financial results are contained in
the Company’s Annual Report on Form 10-K for the year ended
December 31, 2020 under the heading “Risk Factors,” as well as the
Company’s subsequent filings with the Securities and Exchange
Commission. All forward-looking statements included in this press
release are made only as of the date of this press release, and we
do not undertake any obligation to publicly update or correct any
forward-looking statements to reflect events or circumstances that
subsequently occur or of which we hereafter become aware.
For more information:First Wave BioPharma,
Inc.777 Yamato Road, Suite 502Boca Raton, FL 33431Phone: (561)
589-7020info@firstwavebio.com
Media contact:Tiberend Strategic Advisors, Inc.David
Schemelia(609) 468-9325dschemelia@tiberend.com
First Wave BioPharma (NASDAQ:FWBI)
Historical Stock Chart
From Jun 2024 to Jul 2024
First Wave BioPharma (NASDAQ:FWBI)
Historical Stock Chart
From Jul 2023 to Jul 2024